Create Medicines secured a $122 million Series B to advance its in vivo CAR-T pipeline across oncology and autoimmune disease. The Cambridge-based company’s platform uses mRNA-lipid nanoparticle (mRNA-LNP) delivery to instruct T cells, NK cells, and myeloid cells in the body, targeting repeat-dose “immune reset” rather than one-time ex vivo manufacturing. The financing supports programs including CRT-402 (CD19-targeted in vivo CAR T for autoimmune disease), and oncology assets such as MT-303, alongside additional CD19 and BCMA-directed constructs. Create said it has dosed more than 50 patients across in vivo CAR clinical programs and described internal manufacturing as part of its differentiation. A key near-term milestone includes expansion of clinical datasets to support continued progression across multiple therapeutic areas, with an investor syndicate co-leading the round. In an arena where manufacturing bottlenecks have limited CAR-T reach, additional capital for in vivo approaches signals investors’ continued appetite for modalities that attempt to reduce time and infrastructure barriers.